Pharmacokinetics of the KRAS
Dogs
Humans
Mice
Animals
Cytochrome P-450 CYP3A
/ genetics
Carboxylesterase
/ genetics
Proto-Oncogene Proteins p21(ras)
/ metabolism
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Madin Darby Canine Kidney Cells
Mice, Knockout
Lung Neoplasms
/ drug therapy
Brain
/ metabolism
Mice, Transgenic
ATP-Binding Cassette Transporters
/ metabolism
Carboxylic Ester Hydrolases
/ genetics
ATP Binding Cassette Transporter, Subfamily B
/ genetics
ABCB1/P-glycoprotein
ABCG2/Breast cancer resistance protein
Adagrasib
Adagrasib (PubChem CID: 138611145)
Carboxylesterase 1
Cytochrome P450 3A
Elacridar HCl (PubChem CID: 170320)
KRAS(G12C) inhibitor
Ko143 (PubChem CID: 10322450)
Zosuquidar (PubChem CID: 153997)
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
29
03
2023
revised:
01
08
2023
accepted:
07
08
2023
medline:
18
9
2023
pubmed:
16
8
2023
entrez:
16
8
2023
Statut:
ppublish
Résumé
Adagrasib (Krazati™) is the second FDA-approved specific KRAS
Identifiants
pubmed: 37586117
pii: S0753-3322(23)01095-8
doi: 10.1016/j.biopha.2023.115304
pii:
doi:
Substances chimiques
Cytochrome P-450 CYP3A
EC 1.14.14.1
Carboxylesterase
EC 3.1.1.1
adagrasib
8EOO6HQF8Y
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
ATP-Binding Cassette Transporters
0
Carboxylic Ester Hydrolases
EC 3.1.1.-
KRAS protein, human
0
ABCB1 protein, human
0
ATP Binding Cassette Transporter, Subfamily B
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115304Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The research group of A.H. Schinkel receives revenue from commercial distribution of some of the mouse strains used in this study. The other authors have nothing to declare related to this study.